Local infusion of recombinant monocyte chemoattractant protein-1 (MCP-1) has been shown to enhance collateral artery formation in rabbit and pig hindlimb models. Owing to clinical disadvantages of protein infusion, a nonviral, liposome-based MCP-1 gene transfer was developed. Collateralization in a porcine hindlimb model served to provide a proof-of-principle for the functional benefit of MCP-1 overexpression. Development of arterial conductance as a measure of functionally relevant collateralization was evaluated in occluded as well as untreated hindlimbs in each animal. At the time of occlusion, MCP-1 and control DNA/DC-30 lipoplexes were transferred to femoral arteries of Goettingen minipigs (two therapeutic MCP-1 groups: 2 and 4 mg and one control group), using the Infiltrator s local drug-delivery device. At 2 weeks following occlusion, collateralization was determined as changes in peripheral haemodynamic conductance, peripheral over aortic blood pressure ratio and angiographically visible morphology of the peripheral vessel tree. Nonviral MCP-1 gene transfer significantly improved peripheral conductance (control 11.6972.78%, 2 mg 23.8172.81%, Po0.05 and 4 mg 23.3673.1%, Po0.05; n ¼ 12 per group) as well as the ratio of peripheral over aortic blood pressure (control 0.6470.03%, 2 mg 0.7570.02%, Po0.05 and 4 mg 0.7570.02%, Po0.05; n ¼ 12 per group) when compared to the untreated controls 2 weeks after occlusion. Thus, it could be demonstrated for the first time that in situ overexpression of MCP-1 following local nonviral gene transfer is a potential approach to improve peripheral collateralization.
Introduction
Management of peripheral arterial occlusive disease (PAOD) is becoming an increasing challenge. In the US, the age-adjusted prevalence of PAOD is approximately 12%. 1 Symptoms of PAOD include range from intermittent claudication to critical limb ischaemia. The clinical manifestations of the disease depend upon the balance between the time course and extent of collateral vessel growth versus the progression of the disease. Therefore, therapies improving peripheral blood flow by stimulating growth and development of collateral arteries could translate to substantial clinical benefits in mobility, prevention of amputation and quality of life in PAOD patients.
Three distinctive mechanisms of blood vessel formation can be defined: (1) vasculogenesis, by recruiting endothelial progenitor cells from circulation; 2, 3 (2) angiogenesis, involving proliferation and sprouting of endothelial cells (ECs); 4 and (3) arteriogenesis, defined as growth of collateral arteries from preexisting arteriolar connections, requiring the proliferation of ECs and smooth muscle cells and thus the remodelling of the arterial structure by an inflammatory process. 5 Since flow is critically depending on diameter, muscular collateral arteries but not capillaries are supplying sufficient blood to the area at risk in order to prevent the consequences of severe ischaemia.
Under physiological conditions, arteriogenesis is thought to be induced by shear stress occurring in collateral arterioles after a large artery developed a haemodynamically relevant stenosis. Blood flow is redirected through these interconnecting collaterals resulting in the upregulation of endothelial adhesion molecules like intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and selectins 6 as well as monocyte chemoattractant protein-1 (MCP-1). [7] [8] [9] [10] Circulating monocytes activated by MCP-1 attach to endothelium, extravasate, accumulate in the vascular wall and differentiate into macrophages, secreting various cytokines and growth factors (eg basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), tumour necrosis factor-a; granulocytemacrophage colony-stimulating factor (GM-CSF) and MCP-1). 6, 11, 12 MCP-1 is a member of the CC-chemokine family. [13] [14] [15] [16] [17] It has been shown to stimulate arteriogenesis when applied exogenously as a continuous intra-arterial infusion, resulting in a 2.5-fold increase in the magnitude of the arteriogenic response in a rabbit model 18 and in an approximately two-fold increase in a porcine model of PAOD. VEGF or other hypoxia-inducible genes (eg hypoxia-inducible factor-1a, lactate dehydrogenase A) are not associated with arteriogenesis under nonischaemic conditions. 19 This suggests that MCP-1-mediated monocyte activation plays a central role in the process of arteriogenesis and that overexpression of MCP-1 after local gene delivery may be of substantial benefit for patients suffering from PAOD.
The present study was conducted in order to test if nonviral MCP-1 gene transfer induces arteriogenesis in a porcine hindlimb model following permanent acute occlusion of the femoral artery and may thus be suitable for further clinical evaluation with significant advantages to protein infusion approaches. The objective was to provide proof-of-principle for a liposome-based gene transfer approach leading to a local MCP-1 overexpression as well as to investigate the effect of MCP-1 gene expression on peripheral arteriogenesis in a porcine model. Owing to potential difficulties of viral gene transfer approaches in clinical practice such as unexpected severe immunological reactions, the development of a nonviral local gene transfer employing cationic liposomes could provide a major advantage in the treatment of PAOD and other vascular diseases.
Results

In vitro transfection of MCP-1
To test the MCP-1 constructs with respect to the expression of human MCP-1 protein, CHO cells were transfected either with the constructs pAH7 (control), pRZ-hMCP-1-genomic (MCP-1_genomic; BIBH 8) or pRZ-hMCP-1-cDNA (MCP-1_cDNA), and the MCP-1 concentration in the supernatant was determined 72 h after transfection. Analysis of transfected CHO cells labelled by an MCP-1-specific antibody showed positive staining when transfected with both MCP-1_genomic as well as MCP-1_cDNA (Figure 1a(II-III) ); as expected, no MCP-1 protein was detectable in cells transfected with the control plasmid (Figure 1a(I) ). No significant differences in the number of MCP-1-positive cells between MCP-1_genomic-or MCP-1_cDNA-treated cells were observed by immunohistochemistry in six independent experiments (Figure 1a(II-III) ). In contrast, transfection of CHO cells with MCP-1_genomic led to an approximately two-fold higher concentration of secreted MCP-1 protein compared to MCP-1_cDNA (38417165 versus 1826763 ng/ml; n ¼ 6; Po0.0001) (Figure 1b) . Thus, MCP-1_genomic was selected for the in vivo studies due to the higher amount of secreted protein.
Characterization of the porcine model of PAOD Therapeutic local application of MCP-1_genomic and control vector to the A. profunda femoris was performed via an intravascular device followed by an ipsilateral ligation of the femoral artery (Figure 2a) . The untreated and unligated contralateral leg served as an intraindividual reference in subsequent measurements. To select the appropriate observation period in the model, we measured the development of peripheral blood pressure 
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A Muhs et al for 3 weeks after acute ligation of the femoral artery without any treatment as a surrogate for the naturally occurring collateralization (Figure 2b ). The ratio of peripheral over aortic blood pressure dropped directly after ligation to 0.4470.04 (Po0.0001, n ¼ 9) and slightly recovered to 0.5770.03 after 1 week. There was only further minor improvement over 2 (0.6270.04) and 3 weeks postligation (0.5870.06). While peripheral blood pressure remained virtually unchanged in the unligated leg, peripheral blood pressure of ligated legs did not recover to that of untreated legs during the observation period of 3 weeks; the difference between both legs remained statistically significant. For practical reasons and because spontaneous collateralization appeared to have had reached a stable situation between 2 and 3 weeks, measurements in the gene transfer experiments were performed 2 weeks postligation.
In vivo plasmid DNA delivery and MCP-1 expression 
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collateral vessels, neither in number nor in diameter, between the two MCP-1-treated groups (2 and 4 mg MCP-1_genomic).
Improvement of collateral conductance
Peripheral conductance measurements were performed to assess the effect of local MCP-1 transgene overexpression on collateralization and were used to compare the effect of the transfection with the MCP-1 plasmid versus the transfection with a matching empty vector ( Figure 5 ). Conductance was calculated as the ratio of iliac artery blood flow at defined roller pump speed and blood pressure difference between the prestenotic artery (measured at the level of the roller pump) and the poststenotic (peripheral) artery ( Figure  5a ). To assess conductances, pressure difference was plotted against arterial flow and a linear regression by the least-squares method was performed. The slopes for the regression line was calculated ( Figure 5b ) and normalized for the conductance in the unoccluded leg measured synchronously in the same animal. Figure 6 . There was no further increase in peripheral conductance or peripheral blood pressure after transfection with the higher dose of 4 mg, indicating that a maximal effect was already reached after the application of 2 mg MCP-1_genomic.
Discussion
Arteriogenesis, a natural adaptation to a haemodynamically relevant stenosis of large arteries, is stimulated by shear stress, activated endothelium and extravasation of monocytes into the vascular wall initiating collateral artery growth by local secretion of cytokines. 7, 11, 12 Occlusions of large arteries (eg femoral artery 11, 18 or coronary arteries 20 ) either acutely or progressively 21 are established animal models to study both angiogenesis and arteriogenesis as well as effects of therapeutic 
MCP-
Owing to the considerable degree of spontaneous collateralization in rabbits after arterial ligation, 18 the significant difference in size of the arteries between rabbits and humans and the difficulties in applying gene-delivery catheters originally designed for human use to small animals, this study was performed in a porcine model of PAOD. To validate the model and to define its natural time course of recovery, we studied the magnitude of collateralization following occlusion of the femoral artery without any therapeutic intervention. Peripheral collateral blood pressure recovered to approximately 60% of the unoccluded leg 1 week after ligation with no significant further improvement up to 3 weeks. This is in contrast to the time course and magnitude seen in the rabbit model, in which natural collateralization is pronounced enough to virtually restore peripheral blood pressure to preocclusion level after 4 weeks. 22 Thus, the pig hindlimb model reveals significant advantages for testing effects of therapeutic interventions on collateralization and may therefore be of higher predictive value for a clinical setting than, for example, the rabbit model.
MCP-1 protein has been shown to be a potent arteriogenic stimulant when infused in the rabbit femoral artery ligation model over 8 days and in pigs over a 2-week treatment period. 17, 18, 22, 23 Since prolonged administration of MCP-1 in a clinical setting via intraarterial application appears undesirable, a liposomebased nonviral gene transfer to achieve local MCP-1 overexpression and production was developed and 
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tested for efficacy in the pig model. In vitro studies using the genomic MCP-1 (MCP-1_genomic) and the cDNA MCP-1 (MCP-1_cDNA) construct resulted in a similar transfection rate but revealed an increased protein expression for MCP-1_genomic, indicating that mRNA was more efficiently produced from the intron-containing genomic sequence. Assuming that this would translate into the in vivo situation and that increased MCP-1 expression would be therapeutically beneficial, the genomic MCP-1 vector was selected for the in vivo study. The second prerequisite for a successful MCP-1 gene therapy was to ensure delivery of MCP-1 lipoplexes into the vascular wall. PCR as well as RT-PCR measurements were performed to detect the injected vector construct and the expressed MCP-1 mRNA at the target site revealing pronounced signals for both vector doses tested, which indicated the successful delivery.
Since the pilot study showed a stable haemodynamic situation between 1 and 3 weeks after arterial occlusion, angiography was performed 2 weeks after ligation and transfection in order to assess an MCP-1 gene transfermediated effect. An increase in newly detectable collateral vessels revealing the typical corkscrew-like appearance in both MCP-1 dosing groups was found (Figure 4 ). This morphology, identified in our experiments exclusively after MCP-1 treatment, is typical for arteries induced by arteriogenesis. 22, 24 The concomitant increase in the number and diameter of induced collateral arteries are in good agreement with the pronounced increase in peripheral conductance between control-and MCP1_genomic-treated pigs. In addition, other enlarged or induced blood vessels not visualized by angiography may additionally contribute to the peripheral conductance.
To assess peripheral perfusion, flow-pressure relation as well as peripheral blood pressure measurements were performed under flow control and maximal pharmacological arterial dilatation to truly measure the passive properties of the arterial system. The slope of the flowpressure relation (conductance) of the occluded as well as the unoccluded leg was measured and because of marked interindividual differences in the conductance of unoccluded legs between animals, these were expressed as relative values. MCP-1 gene transfer improved the relative arterial conductance two-fold over that in control animals with both administered concentrations of MCP1_genomic. This is comparable to improvements of conductance mediated by continuous infusion of MCP-1 protein in rabbit and pig. 22, 23 The present study showed for the first time that a nonviral gene therapeutic approach was equipotent to a protein perfusion therapy. Transfection of 2 mg MCP-1_genomic led to significant improvements of conductance and to an increase in peripheral blood pressure. Increasing the amount of the genomic MCP-1 plasmid from 2 to 4 mg DNA did not result in an additional increase in the number or diameter of collaterals or peripheral conductance or peripheral blood pressure, indicating that a plateau was reached. Previous pig studies using the same vector, containing iNOS cDNA as insert, in a lipoplex formulation revealed a reduced specific expression below 2 mg of transfected plasmid DNA, which was instructive for the selection of the vector DNA amounts (2 and 4 mg) used in our study. Intriguingly, the lack of a further conductance increase in pigs treated with 4 mg MCP-1_genomic matches perfectly with the maximal expression levels of iNOS in previous pig studies achieved with 2 and 4 mg of vector DNA. 25 In the clinical setting of PAOD slowly developing peripheral arterial occlusion is partially compensated by spontaneous collateral vascular growth as part of an adaptive process. This natural collateralization is highly variable and depends on individual predisposition and (in many cases) is not sufficient to maintain tissue perfusion. Therefore, a therapeutic increase of arteriogenesis appears to be desirable to restore at least part of the necessary blood flow to distal tissues. Whereas most of the growth factors examined so far mediate angiogenesis (eg VEGF, bFGF), [26] [27] [28] [29] [30] recent studies showed that MCP-1 18 and, to a lesser degree, GM-CSF 24 were able to improve arteriogenesis in rabbit models. GM-CSF elevates the local monocyte count by increasing recruitment from the bone marrow and enhancing cell survival. 31 However, protein application of GM-CSF-promoted collateral growth in a small study in patients with coronary artery disease 32 indicated that arteriogenic factors can improve clinically relevant arteriogenesis in man. Based on the superiority of MCP-1 protein infusion over GM-CSF treatment in animal models, MCP-1 gene therapy may be expected to show at least similar effects.
In addition to being a highly potent arteriogenic stimulant, MCP-1 has been indicated to be involved in the pathophysiology of atherosclerosis. [33] [34] [35] [36] Chronic local overexpression of MCP-1 by adenoviral gene transfer resulted in an infiltration of monocytes followed by atherosclerotic lesion formation in rabbits with severe hypercholesterolaemia but not in normal controls. 34 Additionally, an anti-MCP-1 gene therapy approach reduced atherosclerosis and stabilized vulnerable atheromatous plaques in apolipoprotein E-deficient mice. 36 However, given the transient expression typical for nonviral gene transfer and therefore the short duration of exposure, the localized expression at the transfection site and the rapid clearance of secreted MCP-1 from the systemic circulation, fro example, via the Duffy antigen on red blood cells, 37 treatment with nonviral MCP-1 gene transfer is not expected to significantly affect the course of systemic atherosclerosis in man.
In summary, the local overexpression of MCP-1 induced by a nonviral gene transfer approach, described for the first time in the present study, potentially offers a promising therapeutic approach and an attractive alternative to protein infusion in PAODs. Moreover, MCP-1 gene transfer could be an important approach in the treatment of other arterial occlusive diseases, such as coronary artery disease, where a long-term infusion of protein would be even more technically demanding.
Materials and methods
Vector preparation
The pcDNA 3 ampicillin-resistance cassette was replaced by a kanamycin-resistance cassette, amplified from pZErO-2 (Invitrogen) to construct pAH7 (control plasmid). 25 Human genomic MCP-1 sequence (accession no. M37719.1) was amplified from chromosomal HeLa cell DNA to construct pRZ-hMCP-1-genomic (MCP-1_genomic) using the following primers: hMCP-1-F1, pRZ-hMCP-1-genomic was transfected into COS cells lacking MCP-1 expression to derive human MCP-1 cDNA via RT-PCR. The resulting 0.3 kb fragment was cloned into pAH7 to obtain pRZ-hMCP-1-cDNA (MCP1_cDNA). Sequence analysis confirmed the identity of the human MCP-1 cDNA (NCBI accession no. NM_002982).
In vitro transfection of MCP-1
A total of 3 Â 10 5 CHO cells/well were seeded 12 h prior to transfection, resulting in a 80-90% confluence, and transfected with ExGen500 (MBI Fermentas, Germany) utilizing 1.5 mg DNA/construct (constructs tested: pRZhMCP-1-genomic; pRZ-hMCP-1-cDNA, pAH7 control).
MCP-1 immunohistochemistry
CHO cells in chamber slides were fixed in ice-cold methanol for 10 min, washed and incubated in 10% normal goat serum for 40 min to block unspecific binding. The biotinylated mouse-anti-human MCP-1 antibody (BD Biosciences, Germany) was applied for 60 min at 20 mg/ml. Cells were washed in PBS and incubated with the Vectastain Elite-ABC-Kit for alkaline phosphatase (Alexis, Germany) for 45 min. As enzyme substrate, the Vector Red Substrate Kit (Alexis) was used for 30-45 min; cell nuclei were counterstained with Methyl Green (30 s) and slides mounted with Eukitt (Kindler, Germany).
Human MCP-1 ELISA
To quantify MCP-1 secretion, supernatants were collected 72 h after cell transfection and measured in an OptEIA human MCP-1 set (BD Biosciences).
Lipoplexe preparation for in vivo transfection
pAH7 or MCP-1_genomic was complexed to generate MCP-1-lipoplexes with the cationic lipid DAC (3b-(N,N 0 -dimethylaminoethane)-carbamoylcholesterol)-30.romedex, France, a mixture of the monocationic lipid DAC and the neutral colipid dioleoyl-phosphatidylethanolamine. For gene transfer, lyophilized lipoplexes were reconstituted in water.
Animal model
The study protocol was approved by the local ethics review committee. It conformed to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) . Experiments were performed in Goettingen-Minipigs (20-25 kg; Ellegaard, Denmark). Surgical procedures were performed under sterile conditions.
After sedation (25 mg/kg ketamine and 4 mg/kg xylazine), the animals were incubated, ventilated and anaesthesia was maintained using isoflurane. Assessment of arterial conductance as surrogate for peripheral collateralization was performed in three groups of minipigs (4 mg control (pAH7); 2 and 4 mg MCP1_genomic (pRZ-hMCP-1-genomic) lipoplexes; each n ¼ 12). After carotid arteriotomy, each animal was heparinized with a bolus injection of 2500 U heparin. After diagnostic angiography, local A. profunda femoris gene transfer was performed distal to the medial femoral circumflex artery using an intravascular device (Infiltrator s , Boston Scientific, USA) injecting a volume of 400 ml lipoplexes containing 2 mg, 4 mg MCP-1 genomic DNA or 4 mg control DNA, respectively, in the vascular wall.
Femoral artery ligation was performed subsequently by placing two arterial clamps distal to the A. profunda femoris. Angiography was performed in each animal before, directly after gene application, and 2 weeks after ligation under maximal vasodilatation (bolus of 0.2 mg nitroglycerine). To calculate new visible collateral arteries from angiographic movies, the magnification and region of porcine thigh were first defined and standardized. Two independent experts who were blind to the study calculated all new visible collaterals by comparison of angiograms taken directly and 2 weeks after ligation per each animal. Counted arteries were averaged in each groups (n ¼ 12). To assume the luminal diameter of new visible arteries, angiographic pictures were calibrated by standard lead ball with 5 cm diameter. In the middle of collateral total length, the luminal diameter was measured five times. To average the data per group, the mean was calculated from these five measurements, averaged with all new visible collaterals per animal and subsequently summarized with all means of all animals per group (n ¼ 12). At 2 weeks after ligation, arterial animals were killed and conductance was measured. After sedation, anaesthesia, carotid arteriotomy, diagnostic angiography and aortic blood pressure recording, the peripheral blood pressure was measured via puncture of saphena artery. Two ultrasonic flow probes (4.0; Transonics, USA) were placed around each of the external iliac arteries to measure flow to both hindlimbs. The distal abdominal aorta was exposed and cannulated proximal to the bifurcation of the ileac arteries and connected to a roller pump by an extracorporeal by-pass to generate a defined peripheral blood flow. The deep iliac circumflex artery in each untreated leg was exposed and cannulated to measure blood pressure produced by the roller pump. Papaverine (20 mg/min; Sigma, USA) was continuously infused into the perfusion system to achieve maximal local vasodilatation. After a stabilization period, blood flow was increased at equal step by the roller pump speed and was plotted against blood pressure difference between roller pump and periphery. The slope of the resulting linear regression was defined as peripheral conductance. Conductances of the ligated and DNA-transfected legs were compared to the unligated and untreated legs in each animal, expressed in percent and averaged within each group.
PCR and RT-PCR analysis of transfected porcine arteries
Human MCP-1-specific primers (see vector preparation above) and pAH7-specific control primers 25 were used for RT-PCR or PCR analysis. For DNA preparation, homogenates of vessel segments (n ¼ 3 per group) isolated from the transfected region were digested overnight in Proteinase K (600 mAU/ml) and incubated at 551C. DNA was extracted using DNeasy Tissue Kit MCP-1 gene transfer-mediated arteriogenesis A Muhs et al columns (Qiagen, Netherlands). A measure of 300 ng extracted DNA were used in each PCR reaction (5 min 951C, 15 s 941C; 30 s 501C; 30 s 721C (35 cycles), 5 min 721C). For RNA preparation, vessel segments (n ¼ 3 per group) were digested with Proteinase K and extracted with RNeasy columns (Qiagen, Netherlands). RNA (2 mg) were used for reversed transcription (RT reaction) performed for 60 min at 371C. RT reaction (2%) were subjected to a subsequent PCR with human MCP-1-specific primers using the amplification protocol as described above. Porcine-specific beta-actin primer set was used as positive control in RT-PCR. 38 Aliquots of the PCR reaction were analyzed on 1% agarose gels and stained with ethidium bromide.
Statistical analysis
Results are expressed as mean7s.e.m. Statistical analysis was performed using one-way ANOVA (GraphPad Software, USA).
